Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilucoplan Switch Study in gMG
NCT05514873Phase 3Completed
- Sponsor
- UCB
- Start
- Oct 2022
- Primary completion
- Mar 2024
- Modality
- Cyclic Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of zilucoplan in myasthenia gravis (MG), sponsored by UCB. Started Oct 2022; status: completed.
02
Drugs
zilucoplan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05514873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514873.